Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus

Virology

Volumn 476, Issue , 2015, Pages 405-412

  Schell, John B ^a   Bahl, Kapil ^a   Folta Stogniew, Ewa ^a,b   Rose, Nina ^a   Buonocore, Linda ^a   Marx, Preston A ^c   Gambhira, Ratish ^c   Rose, John K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Keck Biophysical Resource Facility   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

Neutralizing antibody; Rhesus macaque; SIVsmE660; Vesicular stomatitis virus; Virus like vesicles

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 140; NEUTRALIZING ANTIBODY; VACCINE; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; IMMUNE RESPONSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS LOAD; ANIMAL; DISEASE MODEL; GENETICS; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; MUCOSA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIROLOGY;

ALPHAVIRUS; ANIMALIA; MACACA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; VESICULAR STOMATITIS VIRUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; HIV; HIV INFECTIONS; HUMANS; MACACA MULATTA; MUCOUS MEMBRANE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84920971383     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.12.027     Document Type: Article

References (33)

1. Abdel-Motal U.M., Sarkis P.T., Han T., Pudney J., Anderson D.J., Zhu Q., et al. Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PloS One 2011, 6:e26473.
2. Balazs A.B., Bloom J.D., Hong C.M., Rao D.S., Baltimore D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat. Biotechnol. 2013, 31:647-652.
3. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482:89-93.
4. Barouch D.H., Whitney J.B., Moldt B., Klein F., Oliveira T.Y., Liu J., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013, 503:224-228.
5. Blasco R., Moss B. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 1995, 158:157-162.
6. Flatz L., Cheng C., Wang L., Foulds K.E., Ko S.Y., Kong W.P., et al. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J. Virol. 2012, 86:7760-7770.
7. Gottardo R., Bailer R.T., Korber B.T., Gnanakaran S., Phillips J., Shen X., et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PloS One 2013, 8:e75665.
8. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
9. Hansen S.G., Piatak M., Ventura A.B., Hughes C.M., Gilbride R.M., Ford J.C., et al. Immune clearance of highly pathogenic SIV infection. Nature 2013, 502:100-104.
10. + T cell epitope recognition paradigms. Science 2013, 340:1237874.
11. Henrich T.J., Hu Z., Li J.Z., Sciaranghella G., Busch M.P., Keating S.M., et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J. Infect. Dis. 2013, 207:1694-1702.
12. Hutter G., Nowak D., Mossner M., Ganepola S., Mussig A., Allers K., et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 2009, 360:692-698.
13. Kassa A., Dey A.K., Sarkar P., Labranche C., Go E.P., Clark D.F., et al. Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein. PloS One 2013, 8:e76139.
14. Keele B.F., Li H., Learn G.H., Hraber P., Giorgi E.E., Grayson T., et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 2009, 206:1117-1134.
15. Kumar R., Tuen M., Liu J., Nadas A., Pan R., Kong X., et al. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines. Vaccine 2013, 31:5413-5421.
16. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012, 37:412-425.
17. Letvin N.L., Rao S.S., Montefiori D.C., Seaman M.S., Sun Y., Lim S.Y., et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci. Transl. Med. 2011, 3:81ra36.
18. Li H., Bar K.J., Wang S., Decker J.M., Chen Y., Sun C., et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog. 2010, 6:e1000890.
19. Manuel E.R., Yeh W.W., Seaman M.S., Furr K., Lifton M.A., Hulot S.L., et al. Dominant CD8+ T-lymphocyte responses suppress expansion of vaccine-elicited subdominant T lymphocytes in rhesus monkeys challenged with pathogenic simian-human immunodeficiency virus. J. Virol. 2009, 83:10028-10035.
20. McCoy L.E., Quigley A.F., Strokappe N.M., Bulmer-Thomas B., Seaman M.S., Mortier D., et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 2012, 209:1091-1103.
21. Patel V., Jalah R., Kulkarni V., Valentin A., Rosati M., Alicea C., et al. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:2975-2980.
22. Pegu P., Vaccari M., Gordon S., Keele B.F., Doster M., Guan Y., et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J. Virol. 2013, 87:1708-1719.
23. Persaud D., Gay H., Ziemniak C., Chen Y.H., Piatak M., Chun T.W., et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 2013, 369:1828-1835.
24. Reynolds M.R., Sacha J.B., Weiler A.M., Borchardt G.J., Glidden C.E., Sheppard N.C., et al. TRIM5{alpha} genotype of rhesus macaques affects acquisition of SIVsmE660 infection after repeated limiting-dose intrarectal challenge. J. Virol. 2011, 85:9637-9640.
25. Rolland M., Edlefsen P.T., Larsen B.B., Tovanabutra S., Sanders-Buell E., Hertz T., et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012, 490:417-420.
26. Rose N.F., Roberts A., Buonocore L., Rose J.K. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J. Virol. 2000, 74:10903-10910.
27. Saez-Cirion A., Bacchus C., Hocqueloux L., Avettand-Fenoel V., Girault I., Lecuroux C., et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013, 9:e1003211.
28. Schell J.B., Rose N.F., Bahl K., Diller K., Buonocore L., Hunter M., et al. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J. Virol. 2011, 85:5764-5772.
29. Schell J.B., Bahl K., Rose N.F., Buonocore L., Hunter M., Marx P.A., et al. Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody. Vaccine 2012, 30:4233-4239.
30. Shingai M., Donau O.K., Plishka R.J., Buckler-White A., Mascola J.R., Nabel G.J., et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 2014, 211:2061-2074.
31. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 2005, 11:615-622.
32. Tully D., Power K., Bedard H., Boutwell C., Charlebois P., Ryan E., et al. A deeper view of transmitted/founder viruses using 454 whole genome deep sequencing. Retrovirology 2012, 9:O58.
33. Zolla-Pazner S., deCamp A.C., Cardozo T., Karasavvas N., Gottardo R., Williams C., et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PloS One 2013, 8:e53629.